Jeffrey S. Parkin

Array ( [id] => 8370194 [patent_doc_number] => 20120219583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-30 [patent_title] => 'NUCLEIC ACID SEQUENCES ENCODING EXPANDABLE HIV MOSAIC PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/502206 [patent_app_country] => US [patent_app_date] => 2010-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 20699 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13502206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6070171 [patent_doc_number] => 20110045021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-24 [patent_title] => 'SUGAR IMMUNOGENS' [patent_app_type] => utility [patent_app_number] => 12/903671 [patent_app_country] => US [patent_app_date] => 2010-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6121 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0045/20110045021.pdf [firstpage_image] =>[orig_patent_app_number] => 12903671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8220824 [patent_doc_number] => 20120135032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-31 [patent_title] => 'GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV' [patent_app_type] => utility [patent_app_number] => 13/389411 [patent_app_country] => US [patent_app_date] => 2010-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13582 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13389411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8509185 [patent_doc_number] => 20120308593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-06 [patent_title] => 'Immunological Compositions for HIV' [patent_app_type] => utility [patent_app_number] => 13/395666 [patent_app_country] => US [patent_app_date] => 2010-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12598 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13395666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8264728 [patent_doc_number] => 20120164153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-28 [patent_title] => 'MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS' [patent_app_type] => utility [patent_app_number] => 13/393622 [patent_app_country] => US [patent_app_date] => 2010-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 16340 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13393622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9502999 [patent_doc_number] => 08741310 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-03 [patent_title] => 'Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies' [patent_app_type] => utility [patent_app_number] => 12/869967 [patent_app_country] => US [patent_app_date] => 2010-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 9 [patent_no_of_words] => 19698 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12869967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6148801 [patent_doc_number] => 20110020396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'HIV Envelope-CD4 Complexes and Hybrids' [patent_app_type] => utility [patent_app_number] => 12/859356 [patent_app_country] => US [patent_app_date] => 2010-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 23474 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020396.pdf [firstpage_image] =>[orig_patent_app_number] => 12859356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6202007 [patent_doc_number] => 20110064793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-17 [patent_title] => 'INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS' [patent_app_type] => utility [patent_app_number] => 12/857043 [patent_app_country] => US [patent_app_date] => 2010-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7125 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20110064793.pdf [firstpage_image] =>[orig_patent_app_number] => 12857043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6201974 [patent_doc_number] => 20110064760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-17 [patent_title] => 'POLYPEPTIDES COMPRISING EPITOPES OF HIV GP41 AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 12/857210 [patent_app_country] => US [patent_app_date] => 2010-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9153 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20110064760.pdf [firstpage_image] =>[orig_patent_app_number] => 12857210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6580467 [patent_doc_number] => 20100291037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-18 [patent_title] => 'IMMUNOGENICITY USING A COMBINATION OF DNA AND VACCINIA VIRUS VECTOR VACCINES' [patent_app_type] => utility [patent_app_number] => 12/845350 [patent_app_country] => US [patent_app_date] => 2010-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 8183 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20100291037.pdf [firstpage_image] =>[orig_patent_app_number] => 12845350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10169364 [patent_doc_number] => 09200065 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-01 [patent_title] => 'Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain' [patent_app_type] => utility [patent_app_number] => 13/382137 [patent_app_country] => US [patent_app_date] => 2010-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 20003 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13382137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8227317 [patent_doc_number] => 20120141527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-07 [patent_title] => 'STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/378929 [patent_app_country] => US [patent_app_date] => 2010-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 41720 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13378929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6126710 [patent_doc_number] => 20110086423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'Cellular Targets for Treatment of Retroviral Infection' [patent_app_type] => utility [patent_app_number] => 12/815125 [patent_app_country] => US [patent_app_date] => 2010-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 15716 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086423.pdf [firstpage_image] =>[orig_patent_app_number] => 12815125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6601781 [patent_doc_number] => 20100322954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-23 [patent_title] => 'ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE' [patent_app_type] => utility [patent_app_number] => 12/796614 [patent_app_country] => US [patent_app_date] => 2010-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13828 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0322/20100322954.pdf [firstpage_image] =>[orig_patent_app_number] => 12796614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6590248 [patent_doc_number] => 20100291680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-18 [patent_title] => 'METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION' [patent_app_type] => utility [patent_app_number] => 12/791983 [patent_app_country] => US [patent_app_date] => 2010-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 84 [patent_no_of_words] => 32926 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20100291680.pdf [firstpage_image] =>[orig_patent_app_number] => 12791983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8227308 [patent_doc_number] => 20120141520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-07 [patent_title] => 'RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS' [patent_app_type] => utility [patent_app_number] => 13/322784 [patent_app_country] => US [patent_app_date] => 2010-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8498 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13322784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8323913 [patent_doc_number] => 20120196306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-02 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION' [patent_app_type] => utility [patent_app_number] => 13/321676 [patent_app_country] => US [patent_app_date] => 2010-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 36052 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13321676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7703155 [patent_doc_number] => 08088910 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-01-03 [patent_title] => 'Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region' [patent_app_type] => utility [patent_app_number] => 12/776893 [patent_app_country] => US [patent_app_date] => 2010-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 10633 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/088/08088910.pdf [firstpage_image] =>[orig_patent_app_number] => 12776893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6486534 [patent_doc_number] => 20100285509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'Melanoma-Associated Endogenous Retrovirus (MERV) Derived Peptide Sequences And Their Therapeutic/Diagnostic Use' [patent_app_type] => utility [patent_app_number] => 12/768076 [patent_app_country] => US [patent_app_date] => 2010-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 6797 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0285/20100285509.pdf [firstpage_image] =>[orig_patent_app_number] => 12768076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6264670 [patent_doc_number] => 20100297610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-25 [patent_title] => 'MOLECULARLY IMPRINTED POLYMERS FOR DETECTING HIV-1' [patent_app_type] => utility [patent_app_number] => 12/761013 [patent_app_country] => US [patent_app_date] => 2010-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11008 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0297/20100297610.pdf [firstpage_image] =>[orig_patent_app_number] => 12761013 [rel_patent_id] =>[rel_patent_doc_number] =>)